Skip to main content
. 2020 Jan 16;128(2):286–295. doi: 10.1152/japplphysiol.00332.2019

Fig. 1.

Fig. 1.

Current overview of signaling pathways leading to the activation of mechanistic target of rapamycin complex 1 (mTORC1). AKT, RAC-alpha serine/threonine-protein kinase; AMPK, AMP-activated protein kinase; ERK 1/2, extracellular signal-regulated kinases 1 and 2; GATOR1/2, GAP activity toward Rags 1/2; IRS-1, insulin receptor substrate 1; LAMTOR 1/2, late endosomal/lysosomal adaptor, MAPK and MTOR activator 1/2; LRS, leucyl-tRNA synthetase; PI3K, phosphatidylinositol-3-kinase; PLD1, phospholipase D1; Rag A/B, C/D, RAS-related GTP-binding protein A/B, C/D; Rheb, Ras homolog enriched in brain; Sestrin2, stress response protein2; SH3BP1, SH3 domain binding protein 4; SLC1A5, solute carrier family 1 member 5; SLC7A5, solute carrier family 7 member 5; SLC38A9, solute carrier family 38 member 9; V-ATPase, vacuolar H+-ATPase. Vps34, vacuolar protein sorting 34.